tissue regeneration, engineering, cell therapy (embryonic/adult) and cell biologies being applied directly to patient care
It occurred to me that in my position performing, directing and reviewing market research on a global scale that it would be worthwhile to highlight recent insights that have come to me regarding the global medical technology market. Some of these insights, of course, may only be meaningful to me (and those who have a [...]
The market for tissue engineering and cell therapy products is set to grow to nearly $32 billion by 2018. This figure includes bioengineered products that are themselves cells or are actively stimulating cell growth or regeneration, products that often represent a combination of biotechnology, medical device and pharmaceutical technologies. The largest segment in the overall [...]
Much attention has been paid to the development of cell therapies with cardiovascular applications. According to the Institute of Cardiovascular Regeneration, more than 1,500 patients with cardiovascular diseases are treated with adult progenitor cells worldwide. Much success has been achieved in this sector and cardiovascular cell therapies are increasingly becoming viable technologies. The primary competitors [...]
Positive results were reported in January 2010 for a GenVec-sponsored trial in which researchers injected gene encoding for tumor necrosis factor-alpha (TNF-alpha) directly into tumors. This led to pathologic complete responses in one-third of the 24 esophageal cancer patients; the median survival was four years. Patients who received the three lowest does of TNF had [...]
Competition in the field of tissue engineering and cell therapy is intense, whether it be attracting top scientists, obtaining licenses to university-owned patents, being the first to reach market with a particular technology, obtaining coveted investment funding, or gaining the attention of larger companies with deeper pockets. With new companies being founded every day, competition [...]
Each year, an estimated 785,000 people in the United States will have a new coronary attack and 470,000 will have a recurrent attack, according to the National Heart, Lung and Blood Institute. In addition, an estimated 195,000 silent myocardial infarctions (MIs) occur each year. Estimated annual incidence of MI is 610,000 new attacks and 325,000 [...]
The search for synthetic-based biocompatible materials has posed particular problems for researchers in that no synthetic material is completely accepted and integrated by the body. Therefore, the goal has been to create a replacement tissue that closely mimics natural tissue and will activate normal body healing and tissue reconstruction, and eventually be resorbed harmlessly into [...]
Tissue engineering and cell therapy comprise a market for regenerative products that is expected to grow worldwide from $6.9 billion in 2009 to almost $32 billion by 2018. This market spans many specialties, the biggest of which is therapies for degenerative and traumatic orthopedic and spine applications. Other disorders that will benefit from cell therapies [...]
One of the most active (by revenue) areas of cell therapy and tissue engineering is in the application of these technologies in orthopedics and spine surgery. It represents the single largest clinical area of sales of these products, driven by the well established tissue grafts business. Active areas include treatments in non-union fractures, cartilage repair, [...]
The subject of "tissue engineering and cell therapy" is, by some accounts, an artificial amalgam of the two separate subjects, particularly since cell therapy per se, as a result of its inextricable link to embryonic stem cells and abortion, seems to demand (at least by some) a wholly separate consideration. From a scientific basis, of [...]
Contact:
